#NASDAQ #Israel #CollPlant #rhCollagen #Rehovot

CollPlant Biotechnologies Faces Compliance Challenge with Nasdaq

CollPlant Biotechnologies, a pioneering company based in Rehovot, Israel, specializing in regenerative and aesthetic medicine, recently announced it has received a notification from the Nasdaq Stock Market.

On March 23, 2026, CollPlant was alerted that it did not meet the minimum bid price requirement of $1.00 per share. This deficiency arises from the company's ordinary shares closing below the stipulated price for the last 30 consecutive business days, as per Nasdaq Listing Rule 5550(a)(2). This ruling is significant, as it flags compliance issues that could potentially lead to delisting from the exchange.

In response to this notification, CollPlant has been granted a compliance period of 180 calendar days, ending on September 21, 2026, to address the shortfall and bring its share price back up to the minimum requirement. To regain compliance, the company must ensure that its closing bid price meets or exceeds $1.00 for at least ten consecutive business days within this compliance window.

Should CollPlant fail to meet this requirement within the set timeframe, it may be eligible for a second compliance period that is also 180 days. However, this will require the company to satisfy the continued listing rules regarding market value and ensure adherence to all other initial listing standards, aside from the minimum bid price requirement. As a potential course of action, CollPlant may need to consider a reverse share split if necessary to elevate the share price.

The company's ordinary shares will continue trading on the Nasdaq Capital Market for the time being, unaffected by the current notice. Nevertheless, CollPlant is keenly monitoring the situation and is engaged in considering the available options to rectify the deficiency and regain compliance. The response showcases the company's proactive stance in addressing what is an undoubtedly critical issue for its visibility and sustainability in the public market.

About CollPlant

Founded on innovative technology, CollPlant focuses on developing groundbreaking products utilizing its proprietary recombinant human collagen (rhCollagen) platform. This platform enables the company to venture into diverse sectors of tissue repair, aesthetics, and even organ manufacturing. Growing its influence, CollPlant recently formed a global partnership with Allergan, a leader in dermal fillers, to develop dermal and soft tissue fillers. CollPlant envisions this partnership as a way to expand its market presence and utilization of advanced bioprinting capabilities.

In the face of these market challenges, the company intends to engage in rigorous measures to nurture its growth, including potential investments to bolster its stock performance. However, like many innovative biotechnology firms, CollPlant faces exponential growth hurdles and inherent risks that accompany the biotechnology landscape, including financial constraints and regulatory scrutiny surrounding clinical trials and product launches.

One thing is clear: the next few months will be pivotal for CollPlant, as it navigates its path towards compliance with Nasdaq and implements strategies to sustain growth in the highly competitive field of regenerative medicine.